How Is Product Classification Determined for Medical Device Registration in South Korea?

Answer: To determine product classification for medical device registration in South Korea, a company should first confirm the target country, the product's risk level, the applicable regulatory pathway, and the existing documentation base, and then assess the technical file, quality management system evidence, labels and instructions for use, the local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extending the project timeline because of unclear classification, documentation, or authorization arrangements.

Published: 2026-07-15 15:46 | Updated: 2026-07-15 15:46. Focusing on international medical device registration, documentation preparation, compliance pathways, and post-market maintenance, this article outlines the issues companies need to prioritize in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI's View
• Frequently Asked Follow-up Questions
• Further Reading
• Applicable Boundaries

Key Summary

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in a target market typically affects the technical file, the authorized representative, importer coordination, label language, quality system evidence, and subsequent change maintenance. If a project is driven only by the question of "which documents must be submitted," corrections or rework can easily arise in model coverage, evidence-chain consistency, labeling claims, and certificate control. AIMEILI recommends positioning this question within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documentation country by country.

Compiled from AIMEILI's regulatory practice question bank, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and on the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for "how to determine product classification for medical device registration in South Korea" are usually not looking for a conceptual explanation. What they actually need to resolve is whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question are usually product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method and duration of body contact, whether the product is sterile, whether it is powered, and whether it includes software or IVD characteristics, and then determine the risk class and submission pathway. Once the pathway is determined incorrectly, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For a target-market project, the applicant entity and local responsibility boundaries must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can be affected later.

Documentation and Evidence

Common documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings, and registration application information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents a company has uploaded.

Common Mistakes

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documentation without reorganizing the evidence according to the target market pathway.
• Including too many models and specifications while test reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent solely on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency among labels, IFUs, promotional materials, and registration documentation, leading to correction requests or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission begins.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation, and English IFUs.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying content that must be re-tested, translated, notarized, or supplemented with declarations.

AIMEILI's View

AIMEILI advises companies not to understand target-market registration as a one-time document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing documentation on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, evidence-chain consistency; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still experience repeated issues in correction, agent communication, and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange re-testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This makes documentation gaps visible promptly and helps management determine whether the project will affect the launch plan.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFUs, clinical evaluation, risk management, performance verification, and quality system certificates, in particular, must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the registered product, or if the manufacturing address, model and specifications, or IFU version are inconsistent with the test report, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Before submission, companies should establish an evidence consistency checklist that matches the product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. This step may appear basic, but it can significantly reduce the probability of correction requests, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation or also undertakes regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, so when a manufacturing address change, model expansion, IFU update, or agent replacement occurs later, the certificate can become disconnected from actual market sales.

AIMEILI recommends incorporating this issue into annual international registration planning: first clarify target-market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but more importantly enabling companies to build a replicable overseas compliance capability and reduce the cost of starting documentation from scratch each time they enter a new market.

Further Reading

Previous: How Should Documentation Be Prepared for Medical Device Registration in South Korea?

Next: How Should the Technical File Be Organized for Medical Device Registration in South Korea?

Recommended reading:

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Are Registration Timelines Extended for Medical Device Registration in Brazil?
• What Are the Common Reasons for Documentation Corrections in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Filed for Medical Device Registration in Brazil?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as supplementary judgment. Applicable boundaries: This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.